Nanovibronix (NASDAQ:FEED – Get Free Report) and Pulse Biosciences (NASDAQ:PLSE – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.
Volatility and Risk
Nanovibronix has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500.
Profitability
This table compares Nanovibronix and Pulse Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nanovibronix | -1,093.61% | -60.73% | -48.48% |
| Pulse Biosciences | -6,755.78% | -94.42% | -79.96% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
| Pulse Biosciences | 1 | 0 | 4 | 1 | 2.83 |
Pulse Biosciences has a consensus price target of $45.25, suggesting a potential downside of 14.12%. Given Pulse Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Pulse Biosciences is more favorable than Nanovibronix.
Institutional and Insider Ownership
16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 12.2% of Nanovibronix shares are held by insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Nanovibronix and Pulse Biosciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nanovibronix | $1.93 million | 0.26 | -$18.18 million | ($117.28) | -0.00 |
| Pulse Biosciences | $350,000.00 | 10,658.43 | -$72.78 million | ($1.18) | -44.65 |
Nanovibronix has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.
Summary
Pulse Biosciences beats Nanovibronix on 9 of the 15 factors compared between the two stocks.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
